WeVote
Log In

Bill

Bill

RC 670

Para ordenar a la Comisión de Salud de la Cámara de Representantes del Gobierno de Puerto Rico realizar una investigación exhaustiva en torno a las prácticas de las aseguradoras relacionadas con cambios en medicamentos, sustituciones terapéuticas, modificaciones en formularios, exclusiones de cubierta, requisitos de preautorización y otros procesos vinculados al beneficio farmacéutico, tanto en la cubierta de salud pública como privada, para evaluar su impacto sobre la continuidad del tratamiento, la notificación efectiva al paciente, la deferencia al criterio médico y la protección de las personas de edad avanzada y demás pacientes vulnerables; y para otros fines relacionados.

2025-2028 Session

The bill directs a thorough inquiry into health insurers’ pharmaceutical benefit practices to assess impacts on ongoing patient care, communications, medical judgment, and protecti

Referido a Comisión(es)
0
WeVote Research Nonpartisan
Bill Summary · RC 670

Summary of Bill RC 670 (Session 2025-2028, Puerto Rico)

1) Purpose and Intent

  • The bill directs the Puerto Rico House of Representatives Health Committee to conduct a comprehensive investigation into the practices of health insurers related to pharmaceutical benefits.
  • Specifically, it examines how insurers handle:
    • Medication changes
    • Therapeutic substitutions
    • Formulary modifications
    • Coverage exclusions
    • Preauthorization requirements
    • Other processes tied to pharmaceutical benefits
  • The overarching goal is to assess the impact of these practices on:
    • Continuity of treatment for patients
    • Effective patient notification
    • Respect for medical judgment
    • Protection of seniors and other vulnerable patient groups
  • The investigation is framed as a means to inform related reforms or actions (“otros fines relacionados”).

2) Key Provisions and Changes Proposed

  • Legislative directive to the Health Committee to:
    • Conduct an exhaustiva (thorough) investigation into insurer practices as they pertain to pharmaceutical benefits in both public and private health coverage.
    • Compile evidence on how changes in medications, formulary management, substitutions, exclusions, and preauthorization affect patient care.
  • Evaluation criteria likely to be used (inferred from purpose, not explicitly enumerated in the brief text):
    • Continuity of treatment (e.g., gaps due to formulary changes or prior authorization delays)
    • Timeliness and clarity of patient communications regarding changes to their medications or coverage
    • Alignment with medical professional judgment and clinical appropriateness
    • Protections for elderly and vulnerable populations
  • The bill does not specify exact regulatory changes but authorizes a formal inquiry that could lead to recommendations or legislative amendments.

3) Affected Parties and Scope

  • Affects:
    • Health insurers operating in Puerto Rico (both public and private plans)
    • Healthcare providers who rely on insurer coverage decisions (prescribers, pharmacies, hospitals)
    • Patients, particularly those who are elderly or medically vulnerable
  • Coverage scope includes both public health coverage and private/individual plans available in Puerto Rico.

4) Procedural and Timeline Aspects

  • Status: Radicado (Filed/Entered) on 2026-04-16
  • Procedural steps already indicated:
    • First Reading in the Chamber (Aparece en Primera Lectura de la Cámara)
    • Referral to relevant Committees (Referido a Comisión(es))
  • Action history suggests ongoing or upcoming committee work, hearings, and a formal report depending on findings.
  • No explicit deadlines, reporting date, or legislative amendments included in the summary text; the inquiry is the immediate procedural step which could culminate in committee reports or proposed legislation.

5) Potential Impacts and Implications

  • If a thorough investigation yields significant findings, potential outcomes may include:
    • Legislative or regulatory measures to strengthen patient notification requirements for formulary changes and prior authorization
    • Policies to safeguard continuity of care during formulary transitions or therapeutic substitutions
    • Protections or tailored interventions for seniors and vulnerable patients
    • Transparency improvements in insurer practices relating to drug coverage decisions
  • The bill’s evidence-based approach could facilitate targeted reforms without immediate, broad regulatory changes, depending on committee recommendations.

If you’d like, I can convert this into a one-page briefing for policymakers or draft potential questions for committee hearings based on the bill’s focus.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.